LL-37 vs Thymosin Alpha 1: The Difference

LL-37 and Thymosin Alpha 1 are both grouped under "immunomodulation" in the research literature, but they come from different biological systems, have different structures, and get studied to answer different questions. LL-37 is a fragment of a human cathelicidin with direct antimicrobial activity. Thymosin Alpha 1 is a peptide derived from a prohormone originally produced by the thymus, and the activity studied in the literature is regulation of T-cell response, not direct action against microorganisms.

That is the core difference. Everything else — size, mechanism, which research models use each one — follows from it.

What is LL-37

LL-37 is the only cathelicidin peptide identified in humans. It is released from the precursor hCAP-18 and consists of 37 amino acids, which is where the name comes from (it starts with two leucines, "LL", and has 37 residues). It is studied mainly for:

• Broad-spectrum antimicrobial activity: the literature describes effects against gram-positive and gram-negative bacteria, fungi, and some enveloped viruses, through a mechanism that disrupts the microorganism's membrane rather than targeting a specific molecular receptor.
• Wound healing: animal and cell-model studies have examined its role in tissue repair and angiogenesis.
• Innate immunity: it does not wait for the adaptive immune system to recognize a pathogen — it acts as a first line of defense.

Structurally, LL-37 is a cationic, amphipathic peptide: part of the molecule carries a positive charge and part is hydrophobic, which lets it interact with the negatively charged bacterial membrane. That physical mechanism is what sets it apart from most peptides that act on a specific receptor.

What is Thymosin Alpha 1

Thymosin Alpha 1 (Tα1) is a 28-amino-acid peptide, shorter than LL-37, and its biological origin is entirely different: it was first isolated from bovine thymus extract and corresponds to the N-terminal region of prothymosin alpha.

Its field of study is regulation of the adaptive immune response, not direct action against microorganisms:

• T-cell maturation and function: the literature describes it modulating the differentiation and activity of T-cell subpopulations.
• Immunosenescence research models: it is studied in the context of how immune function declines with age.
• Oncology and infectious-disease research models: some research lines examine its role alongside other therapies in cancer and chronic viral infection models, looking at its effect on the host's immune response rather than a direct antimicrobial effect.

Unlike LL-37, which acts physically on a membrane, Tα1 is studied as a signaling molecule: it interacts with Toll-like receptors on dendritic cells and affects intracellular signaling pathways, a mechanism much closer to that of a cytokine than to a membrane-active antimicrobial.

The differences that matter for a research protocol

Laid out plainly, the central differences between the two peptides are:

• Biological origin: LL-37 comes from the cathelicidin system of cutaneous and neutrophil innate immunity. Tα1 comes from the thymus and the adaptive-immunity axis.
• Size: LL-37 has 37 amino acids; Tα1 has 28.
• Mechanism of action: LL-37 acts through physical disruption of microbial membranes. Tα1 acts through receptor-mediated signaling.
• Focus of activity: LL-37 is studied as an antimicrobial and modulator of wound healing. Tα1 is studied as a regulator of T-cell function.
• Charge and structure: LL-37 is markedly cationic and amphipathic, a structure optimized to interact with membrane lipids. Tα1 has an acidic structure with no membrane-binding function.

Where they overlap

They share the "immunomodulator" label in the literature for a real reason: both intervene in the immune response of the system being studied, and both appear cited in reviews of endogenous peptides with immunological relevance. But one acts at the point of entry, directly against the microorganism, and the other acts internally, regulating how the immune cells themselves respond. Confusing the two in an experimental design leads to choosing the wrong peptide for the question being asked.

Documentation and material provenance

Any peptide used in a research protocol needs traceability: which batch it came from, which laboratory analyzed it, and by what method. PeptoClinic works with third-party purity reports from labs such as Janoshik Analytical for material that has a published report, and applies the same documentation standard — HPLC purity of 99% or higher — across everything in the catalog. Before adding a new peptide to a protocol, it is worth requesting the certificate of analysis for that specific batch rather than assuming the general catalog standard applies automatically to every compound.

For research programs also working with tissue-repair or mitochondrial peptides, it is worth reviewing KPV, studied in models of skin inflammation, and comparing its mechanism with BPC-157, which acts on repair pathways distinct from the two molecules covered in this article. Researchers sourcing either compound for programs based in Argentina can review the documentation PeptoClinic prepares for shipments to Argentina.

Research use only

LL-37 and Thymosin Alpha 1, like all material PeptoClinic supplies, are provided exclusively for laboratory research (Research Use Only, RUO): in vitro studies and experimental models. Neither peptide is approved or intended for human or veterinary consumption, diagnosis, or treatment of any condition. Nothing in this article constitutes administration, dosing, or protocol guidance for use in people, and no claim here has been evaluated by the FDA, ANMAT, or any equivalent regulatory authority. PeptoClinic operates as a technical supply consultancy for research material, ships to research destinations with customs documentation prepared for laboratory reference material, and does not issue or require a medical prescription.